Roche NT-proBNP CHF Test Launch Expected By Jan. Pending FDA Approval
This article was originally published in The Gray Sheet
Executive Summary
Roche expects its NT-proBNP N-terminal pro-B-type natriuretic peptide diagnostic for chronic heart failure to cost less than competitor BioSite's Triage point of care test
You may also be interested in...
Roche Diagnostics Inks Second ProBNP Test Development Deal
Syn X Pharma aims to bring its NT-proBNP Nexus Dx point-of-care test for the detection of congestive heart failure to the U.S. market by the second half of 2004
Roche Diagnostics Inks Second ProBNP Test Development Deal
Syn X Pharma aims to bring its NT-proBNP Nexus Dx point-of-care test for the detection of congestive heart failure to the U.S. market by the second half of 2004
Abbott AxSYM U.S. Presence May Give Firm Edge Over BNP Competitors
Abbott will try to leverage its installed U.S. base of 5,000 AxSYM automated analyzers to gain a competitive advantage over Bayer Diagnostics as each firm prepares a 2003 launch of a B-type natriuretic peptide (BNP) test to help diagnose congestive heart failure